Literature DB >> 22271887

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.

Matteo G Della Porta, Ilaria Ambaglio, Marta Ubezio, Erica Travaglino, Cristiana Pascutto, Luca Malcovati.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22271887      PMCID： PMC3347673          DOI： 10.3324/haematol.2011.057323

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

2.  Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

Authors:  Massimo Breccia; Vincenzo Federico; Roberto Latagliata; Caterina Mercanti; Gianna Maria D'Elia; Laura Cannella; Giuseppina Loglisci; Adriano Salaroli; Michelina Santopietro; Giuliana Alimena
Journal:  Leuk Res       Date:  2010-07-01       Impact factor: 3.156

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Authors:  Luca Malcovati; Matteo G Della Porta; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Kathrin Nachtkamp; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2011-06-09       Impact factor: 9.941

5.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors:  Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

6.  Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.

Authors:  Kiran Naqvi; Guillermo Garcia-Manero; Sagar Sardesai; Jeong Oh; Carlos E Vigil; Sherry Pierce; Xiudong Lei; Jianqin Shan; Hagop M Kantarjian; Maria E Suarez-Almazor
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

7.  Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.

Authors:  Matteo Giovanni Della Porta; Luca Malcovati
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

8.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Authors:  Esther Zipperer; Daniela Pelz; Kathrin Nachtkamp; Andrea Kuendgen; Corinna Strupp; Norbert Gattermann; Rainer Haas; Ulrich Germing
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

9.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.